ONCOMATRYX, a biopharmaceutical company developing Quantum ADCs targeting the tumor microenvironment, has secured $67 million in funding. This capital will accelerate the clinical development of their novel drug candidates. The round saw significant investment from institutional backers, including a $28 million strategic contribution from the Spanish Government via CDTI.
Amount: $67.0M
